Periodate-treated, Non-anticoagulant Heparin-carrying Polystyrene (NAC-HCPS) Affects Angiogenesis and Inhibits Subcutaneous Induced Tumour Growth and Metastasis to the Lung

Overview

Journal Br J Cancer

Specialty Oncology

Date 2002 Jun 28

PMID 12087470

Citations 23

Authors

K Ono

M Ishihara

K Ishikawa

Y Ozeki

H Deguchi

M Sato

H Hashimoto

Y Saito

H Yura

A Kurita

T Maehara

Affiliations

Soon will be listed here.

Abstract

Periodate-treated, non-anticoagulant heparin-carrying polystyrene consists of about ten periodate-oxidized, alkaline-degraded low molecular weight-heparin chains linked to a polystyrene core and has a markedly lower anti-coagulant activity than heparin. In this study, we evaluated the effect of non-anticoagulant heparin-carrying polystyrene on tumour growth and metastasis. Non-anticoagulant heparin-carrying polystyrene has a higher activity to inhibit vascular endothelial growth factor-165-, fibroblast growth factor-2- or hepatocyte growth factor-induced human microvascular endothelial cell growth than heparin, ten periodate-oxidized-heparin and ten periodate-oxidized-low molecular weight-heparin, which is probably due to the heparin-clustering effect of non-anticoagulant heparin-carrying polystyrene. Non-anticoagulant heparin-carrying polystyrene inhibited human microvascular endothelial cell, B16 melanoma and Lewis lung cancer cell adhesion to Matrigel-coated plates. Non-anticoagulant heparin-carrying polystyrene also showed strong inhibitory activities in the tubular formation of endothelial cells on Matrigel and B16-melanoma and Lewis lung cancer cell invasion in a Matrigel-coated chamber assay. In vivo studies showed that growth of subcutaneous induced tumours and lung metastasis of B16-melanoma and Lewis lung cancer cells were more effectively inhibited by non-anticoagulant heparin-carrying polystyrene than ten periodate-oxidized-heparin and ten periodate-oxidized-low molecular weight-heparin. Furthermore, non-anticoagulant heparin-carrying polystyrene markedly reduced the number of CD34-positive vessels in subcutaneous Lewis lung cancer tumours, indicating a strong inhibition of angiogenesis. These results suggest that non-anticoagulant heparin-carrying polystyrene has an inhibitory activity on angiogenesis and tumour invasion and may be very useful in cancer therapy.

Citing Articles

Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis.

Asmael Al-Azzawi H, Hamza S, Paolini R, Arshad F, Patini R, OReilly L Front Oral Health. 2024; 5:1495942.

PMID: 39568788 PMC: 11576436. DOI: 10.3389/froh.2024.1495942.

Concomitant heparin use promotes skin graft donor site healing by basic fibroblast growth factor: A pilot prospective randomized controlled study.

Kohyama K, Kato H, Okada H, Ishihara T, Yasue Y, Kamidani R Contemp Clin Trials Commun. 2024; 42:101375.

PMID: 39398328 PMC: 11470421. DOI: 10.1016/j.conctc.2024.101375.

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.

Quan Y, He J, Zou Q, Zhang L, Sun Q, Huang H J Immunother Cancer. 2023; 11(8).

PMID: 37597850 PMC: 10441131. DOI: 10.1136/jitc-2023-007080.

Non-anticoagulant heparin derivatives for COVID-19 treatment.

Cao M, Qiao M, Sohail M, Zhang X Int J Biol Macromol. 2022; 226:974-981.

PMID: 36528145 PMC: 9749384. DOI: 10.1016/j.ijbiomac.2022.12.090.

Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.

Berdiaki A, Neagu M, Giatagana E, Kuskov A, Tsatsakis A, N Tzanakakis G Biomolecules. 2021; 11(3).

PMID: 33800172 PMC: 8001210. DOI: 10.3390/biom11030395.

References

Ishihara M, Saito Y, Yura H, Ono K, Ishikawa K, Hattori H . Heparin-carrying polystyrene to mediate cellular attachment and growth via interaction with growth factors. J Biomed Mater Res. 2000; 50(2):144-52. DOI: 10.1002/(sici)1097-4636(200005)50:2<144::aid-jbm8>3.0.co;2-s. View

Basbaum C, Werb Z . Focalized proteolysis: spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol. 1996; 8(5):731-8. DOI: 10.1016/s0955-0674(96)80116-5. View

Dvorak H, Harvey V, Estrella P, Brown L, McDonagh J, Dvorak A . Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987; 57(6):673-86. View

Gogly B, Hornebeck W, Groult N, Godeau G, Pellat B . Influence of heparin(s) on the interleukin-1-beta-induced expression of collagenase, stromelysin-1, and tissue inhibitor of metalloproteinase-1 in human gingival fibroblasts. Biochem Pharmacol. 1998; 56(11):1447-54. DOI: 10.1016/s0006-2952(98)00257-3. View

Fransson L, Carlstedt I . Alkaline and smith degradation of oxidized dermatan sulphate-chondroitin sulphate copolymers. Carbohydr Res. 1974; 36(2):349-58. DOI: 10.1016/s0008-6215(00)83056-6. View

Smorenburg S, Van Noorden C . The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001; 53(1):93-105. View

Nehls V, Herrmann R . The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. Microvasc Res. 1996; 51(3):347-64. DOI: 10.1006/mvre.1996.0032. View

Kenagy R, Nikkari S, Welgus H, Clowes A . Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest. 1994; 93(5):1987-93. PMC: 294307. DOI: 10.1172/JCI117191. View

ENGELBERG H . Actions of heparin that may affect the malignant process. Cancer. 1999; 85(2):257-72. DOI: 10.1002/(sici)1097-0142(19990115)85:2<257::aid-cncr1>3.0.co;2-2. View

10.

Zacharski L, Ornstein D . Heparin and cancer. Thromb Haemost. 1998; 80(1):10-23. View

11.

Westermarck J, Kahari V . Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13(8):781-92. View

12.

Conrad H, Guo Y . Structural analysis of periodate-oxidized heparin. Adv Exp Med Biol. 1992; 313:31-6. DOI: 10.1007/978-1-4899-2444-5_3. View

13.

Bourin M, Lindahl U . Glycosaminoglycans and the regulation of blood coagulation. Biochem J. 1993; 289 ( Pt 2):313-30. PMC: 1132170. DOI: 10.1042/bj2890313. View

14.

. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998; 77(1):1-10. PMC: 2151254. DOI: 10.1038/bjc.1998.1. View

15.

Albini A, Iwamoto Y, Kleinman H, Martin G, Aaronson S, Kozlowski J . A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 1987; 47(12):3239-45. View

16.

Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsuchida T . Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer. 2000; 36(18):2390-6. DOI: 10.1016/s0959-8049(00)00343-9. View

17.

Lapierre F, Holme K, Lam L, Tressler R, Storm N, Wee J . Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 1996; 6(3):355-66. DOI: 10.1093/glycob/6.3.355. View

18.

TOMISAWA M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H . Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999; 35(1):133-7. DOI: 10.1016/s0959-8049(98)00278-0. View

19.

McCarthy J, Skubitz A, Qi Z, Yi X, Mickelson D, Klein D . RGD-independent cell adhesion to the carboxy-terminal heparin-binding fragment of fibronectin involves heparin-dependent and -independent activities. J Cell Biol. 1990; 110(3):777-87. PMC: 2116046. DOI: 10.1083/jcb.110.3.777. View

20.

Irimura T, Nakajima M, Nicolson G . Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry. 1986; 25(18):5322-8. DOI: 10.1021/bi00366a050. View